Presentation is loading. Please wait.

Presentation is loading. Please wait.

Early Clinical Development High Resolution PK/PD in Phase I to Guide Subsequent Development: Experience with Remifentanil Steven L. Shafer, M.D. Palo Alto.

Published by Modified over 9 years ago

Similar presentations

Presentation on theme: "Early Clinical Development High Resolution PK/PD in Phase I to Guide Subsequent Development: Experience with Remifentanil Steven L. Shafer, M.D. Palo Alto."— Presentation transcript:

1 Early Clinical Development High Resolution PK/PD in Phase I to Guide Subsequent Development: Experience with Remifentanil Steven L. Shafer, M.D. Palo Alto VA Health Care System Stanford University School of Medicine

2 Lecture Goals l Explain opioid concentration/effect relationships l Explain EEG measures of opioid drug effect l Introduce opioid “fingerprint” using EEG as a surrogate measure of drug effect l Explain how the EEG established remifentanil therapeutic windows in Phase I l Demonstrate how Phase I PK/PD affected Phase II and III study design and drug labeling

3 Acknowledgements l Donald Stanski, M.D. (Stanford) l Keith Muir, Ph.D. (Glaxo) l Robert Powell, M.D. (Glaxo) l Talmage Egan, M.D. (Stanford) l Charles Minto, M.D. (Stanford) l Thomas Schinder, M.D. (Stanford) l Dan Spyker, M.D. (FDA)

4 Alfentanil Clinical Concentration vs Response Ausems ME, Hug CC, Stanski DR, Burm AGL: Anesthesiology 65:362-373, 1986

5 Alfentanil Concentration- Response Relationships Egan, et al. The role of the EEG in Remifentanil Development.

6 Opioid Therapeutic Ranges Billard V, Shafer SL. Control and Automation in Anesthesia. 1995, Springer

7 Awake EEG Gregg K, Varvel JR, Shafer SL. J Pharmacokinet Biopharm 20, 611-635, 1992

8 Profound Opioid EEG Effect Gregg K, Varvel JR, Shafer SL. J Pharmacokinet Biopharm 20, 611-635, 1992

9 EEG Time Course with Fentanyl Scott J, Ponganis KV, Stanski DR. Anesthesiology 62:234-241, 1985

10 EEG Time Course with Alfentanil Scott J, Ponganis KV, Stanski DR. Anesthesiology 62:234-241, 1985

11 Fentanyl, Alfentanil, Sufentanil EEG Billard V, Shafer SL. Control and Automation in Anesthesia. 1995, Springer

12 EEG Response as a fraction of IC 50 Billard V, Shafer SL. Control and Automation in Anesthesia. 1995, Springer

13 EEG vs Therapeutic Ranges Billard V, Shafer SL. Control and Automation in Anesthesia. 1995, Springer

14 EEG vs Opioid Therapeutic Ranges Billard V, Shafer SL. Control and Automation in Anesthesia. 1995, Springer

15 EEG Time Course with Remifentanil Egan, et al. Anesthesiology 84:881-833, 1996

16 Fentanyl Congener EEG Pharmacodynamic Parameters Egan, et al. The role of the EEG in Remifentanil Development.

17 Remifentanil Therapeutic Ranges

18 Remifentanil Dosing Based on Phase I PK/PD

19 Remifentanil Time Course Egan, et al. The role of the EEG in Remifentanil Development.

20 Relative Therapeutic Windows Egan, et al. The role of the EEG in Remifentanil Development.

21 Opioid Fingerprint, 1997 Egan, et al. The role of the EEG in Remifentanil Development.

22 Remifentanil Fingerprint Egan, et al. The role of the EEG in Remifentanil Development.

Download ppt "Early Clinical Development High Resolution PK/PD in Phase I to Guide Subsequent Development: Experience with Remifentanil Steven L. Shafer, M.D. Palo Alto."

Similar presentations

Advances in the Clinical Pharmacology of Intravenous Anesthetics : Pharmacokinetic, Pharmacodynamic, Pharmaceutical, and Technological Considerations R3.

Advances in the Clinical Pharmacology of Intravenous Anesthetics : Pharmacokinetic, Pharmacodynamic, Pharmaceutical, and Technological Considerations R3.
The Drug Discovery Process

The Drug Discovery Process
Matthew M. Riggs, Ph.D. metrum research group LLC

Matthew M. Riggs, Ph.D. metrum research group LLC
Small Molecule PD and Imaging – Models and Assay Development DCTD Phase 0 Primer, September 5, 2007 Ralph E Parchment, PhD SAIC-Frederick, Inc., NCI-Frederick,

Small Molecule PD and Imaging – Models and Assay Development DCTD Phase 0 Primer, September 5, 2007 Ralph E Parchment, PhD SAIC-Frederick, Inc., NCI-Frederick,
Ramana S. Uppoor, M.Pharm., Ph.D., R.Ph.

Ramana S. Uppoor, M.Pharm., Ph.D., R.Ph.
Clinical Pharmacokinetics

Clinical Pharmacokinetics
HOW CAN NEUROIMAGING HELP UNDERSTAND, DIAGNOSE, AND DEVELOP TREATMENTS FOR ALZHEIMER'S DISEASE? Part D1 – AD brain scans – perfusion SPECT NUCLEAR MEDICINE.

HOW CAN NEUROIMAGING HELP UNDERSTAND, DIAGNOSE, AND DEVELOP TREATMENTS FOR ALZHEIMER'S DISEASE? Part D1 – AD brain scans – perfusion SPECT NUCLEAR MEDICINE.
HOW CAN NEUROIMAGING HELP UNDERSTAND, DIAGNOSE, AND DEVELOP TREATMENTS FOR ALZHEIMER'S DISEASE? Part D2 – AD brain scans – metabolism - PET NUCLEAR MEDICINE.

HOW CAN NEUROIMAGING HELP UNDERSTAND, DIAGNOSE, AND DEVELOP TREATMENTS FOR ALZHEIMER'S DISEASE? Part D2 – AD brain scans – metabolism - PET NUCLEAR MEDICINE.
1 Xavier University of Louisiana College of Pharmacy Curriculum Map – NAPLEX Competencies Map by Course.

1 Xavier University of Louisiana College of Pharmacy Curriculum Map – NAPLEX Competencies Map by Course.
1 PK/PD modeling within regulatory submissions Is it used? Can it be used and if yes, where? Views from industry 24 September 2008.

1 PK/PD modeling within regulatory submissions Is it used? Can it be used and if yes, where? Views from industry 24 September 2008.
1 Efficacy and Safety of 3 Different IV Doses of Palonosetron for the Prevention of PONV in the Outpatient (Study 1) and Inpatient (Study 2) Settings Study.

1 Efficacy and Safety of 3 Different IV Doses of Palonosetron for the Prevention of PONV in the Outpatient (Study 1) and Inpatient (Study 2) Settings Study.
Improvement in Dose Selection Through Clinical Applications of PK/PD in Antimicrobial Drug Development Hartmut Derendorf, Ph.D. University of Florida.

Improvement in Dose Selection Through Clinical Applications of PK/PD in Antimicrobial Drug Development Hartmut Derendorf, Ph.D. University of Florida.
Early Clinical Development High Resolution PK/PD in Phase I to Guide Subsequent Development: Experience with Remifentanil Steven L. Shafer, M.D. Palo Alto.

Early Clinical Development High Resolution PK/PD in Phase I to Guide Subsequent Development: Experience with Remifentanil Steven L. Shafer, M.D. Palo Alto.
© 2006 McGraw-Hill Higher Education. All rights reserved. Chapter 5 The Actions of Drugs.

© 2006 McGraw-Hill Higher Education. All rights reserved. Chapter 5 The Actions of Drugs.
“FUTURE CONSIDERATIONS FOR PK/PD RESEARCH” Terrence F. Blaschke, M.D. Professor of Medicine and Molecular Pharmacology Stanford University.

“FUTURE CONSIDERATIONS FOR PK/PD RESEARCH” Terrence F. Blaschke, M.D. Professor of Medicine and Molecular Pharmacology Stanford University.
Overview of Use of PK-PD in Streamlining Drug Development William A. Craig Professor of Medicine University of Wisconsin.

Overview of Use of PK-PD in Streamlining Drug Development William A. Craig Professor of Medicine University of Wisconsin.
2010 Typical American Hospital 1985 - 25 years ago Typical American Hospital.

2010 Typical American Hospital years ago Typical American Hospital.
Office of Clinical Pharmacology and Biopharmaceutics IDSA/ISAP/FDA Workshop 4/16/04 1 Improvement in Dose Selection: FDA Perspective IDSA/ISAP/FDA Workshop.

Office of Clinical Pharmacology and Biopharmaceutics IDSA/ISAP/FDA Workshop 4/16/04 1 Improvement in Dose Selection: FDA Perspective IDSA/ISAP/FDA Workshop.
Eureka Pre-Clinical Investigation Animal toxicology Animal pharmacokinetics/ pharmacodynamics Clinical Investigation Phase I Safety and pharmacology Phase.

Eureka Pre-Clinical Investigation Animal toxicology Animal pharmacokinetics/ pharmacodynamics Clinical Investigation Phase I Safety and pharmacology Phase.
Office of Clinical Pharmacology and Biopharmaceutics IDSA/ISAP/FDA Workshop 4/16/04 In Vitro/Animal Models to Support Dosage Selection: FDA Perspective.

Office of Clinical Pharmacology and Biopharmaceutics IDSA/ISAP/FDA Workshop 4/16/04 In Vitro/Animal Models to Support Dosage Selection: FDA Perspective.

Similar presentations

Ads by Google